New hope for elderly colorectal cancer patients: triple therapy shows promise

NCT ID NCT03451370

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how well a combination of three drugs—capecitabine, oxaliplatin, and bevacizumab—works as a first treatment for elderly patients (70 and older) with metastatic colorectal cancer that cannot be removed by surgery. The goal is to see if this approach can delay cancer growth in real-world practice. The study enrolled 121 participants and is no longer recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
capecitabine, oxaliplatin, and bevacizumab
What this could lead to
If successful, this could confirm a safe and effective first-line treatment option for elderly patients with metastatic colorectal cancer, potentially improving progression-free survival.
What could go wrong
This is an observational study, not a randomized trial, so results may be less definitive. The combination carries risks of chemotherapy side effects like nerve damage, fatigue, and gastrointestinal issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ELDERLY METASTATIC COLORECTAL CANCER PATIENTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Istituto Oncologico Veneto IRCCS

    Padua, 35128, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.